Furthermore, they identified a novel compound able to block the association between hnRNPA1 and its IRES structure localized on c-myc and cyclin D1 which therefore blocks c-myc and cyclin D1 translation and consequently sensitizes GBM cells to mTOR inhibitors. The gene discussed is MYC; the disease is glioblastoma.